JP2015501783A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015501783A5 JP2015501783A5 JP2014539998A JP2014539998A JP2015501783A5 JP 2015501783 A5 JP2015501783 A5 JP 2015501783A5 JP 2014539998 A JP2014539998 A JP 2014539998A JP 2014539998 A JP2014539998 A JP 2014539998A JP 2015501783 A5 JP2015501783 A5 JP 2015501783A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- pharmaceutical composition
- following formula
- acceptable carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YFISEEHEDYLAHH-UHFFFAOYSA-N Cc1ncc(CCc2cc3nc(C(N)=O)cc(-c(ccc(OC)c4)c4F)c3cc2)cn1 Chemical compound Cc1ncc(CCc2cc3nc(C(N)=O)cc(-c(ccc(OC)c4)c4F)c3cc2)cn1 YFISEEHEDYLAHH-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161555227P | 2011-11-03 | 2011-11-03 | |
| US61/555,227 | 2011-11-03 | ||
| US201261672334P | 2012-07-17 | 2012-07-17 | |
| US61/672,334 | 2012-07-17 | ||
| PCT/US2012/062027 WO2013066736A1 (en) | 2011-11-03 | 2012-10-26 | QUINOLINE CARBOXAMIDE AND QUINOLINE CARBONITRILE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015242916A Division JP6114809B2 (ja) | 2011-11-03 | 2015-12-14 | ｍＧｌｕＲ２−陰性アロステリック調節因子としてのキノリンカルボキサミドおよびキノリンカルボニトリル誘導体、組成物、およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015501783A JP2015501783A (ja) | 2015-01-19 |
| JP2015501783A5 true JP2015501783A5 (enExample) | 2015-12-24 |
| JP5857136B2 JP5857136B2 (ja) | 2016-02-10 |
Family
ID=48192643
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014539998A Expired - Fee Related JP5857136B2 (ja) | 2011-11-03 | 2012-10-26 | ｍＧｌｕＲ２−陰性アロステリック調節因子としてのキノリンカルボキサミドおよびキノリンカルボニトリル誘導体、組成物、およびその使用 |
| JP2015242916A Expired - Fee Related JP6114809B2 (ja) | 2011-11-03 | 2015-12-14 | ｍＧｌｕＲ２−陰性アロステリック調節因子としてのキノリンカルボキサミドおよびキノリンカルボニトリル誘導体、組成物、およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015242916A Expired - Fee Related JP6114809B2 (ja) | 2011-11-03 | 2015-12-14 | ｍＧｌｕＲ２−陰性アロステリック調節因子としてのキノリンカルボキサミドおよびキノリンカルボニトリル誘導体、組成物、およびその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US9278960B2 (enExample) |
| EP (1) | EP2775841B1 (enExample) |
| JP (2) | JP5857136B2 (enExample) |
| KR (1) | KR20140088887A (enExample) |
| CN (1) | CN104010504B (enExample) |
| AR (1) | AR088611A1 (enExample) |
| AU (2) | AU2012332895B2 (enExample) |
| CA (1) | CA2853923A1 (enExample) |
| CO (1) | CO6950474A2 (enExample) |
| IL (1) | IL232291A0 (enExample) |
| IN (1) | IN2014CN03234A (enExample) |
| MX (1) | MX344308B (enExample) |
| MY (1) | MY167423A (enExample) |
| RU (1) | RU2610262C2 (enExample) |
| TW (1) | TWI605040B (enExample) |
| WO (1) | WO2013066736A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX344308B (es) | 2011-11-03 | 2016-12-13 | Merck Sharp & Dohme | Derivados de quinolina carboxamida y quinolina carbonitrilo como moduladores alostericos negativos de mglur2, composiciones y su uso. |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| PE20170331A1 (es) | 2014-03-24 | 2017-04-28 | Guangdong Zhongsheng Pharmaceutical Co Ltd | Derivados quinolina como inhibidores smo |
| JOP20150177B1 (ar) | 2014-08-01 | 2021-08-17 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
| WO2016016382A1 (en) | 2014-08-01 | 2016-02-04 | Janssen Pharmaceutica Nv | 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors |
| JO3601B1 (ar) | 2014-08-01 | 2020-07-05 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
| EP3174884B1 (en) | 2014-08-01 | 2018-09-26 | Janssen Pharmaceutica NV | 6,7-dihydropyrazolo[1,5- ]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglu2 receptors |
| JOP20150179B1 (ar) * | 2014-08-01 | 2021-08-17 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
| WO2016029454A1 (en) | 2014-08-29 | 2016-03-03 | Merck Sharp & Dohme Corp. | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE |
| EP3000814A1 (en) | 2014-09-26 | 2016-03-30 | Domain Therapeutics | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors |
| JP6861154B2 (ja) | 2014-12-03 | 2021-04-21 | ヤンセン ファーマシューティカ エヌ．ベー． | 放射標識されたｍＧｌｕＲ２ ＰＥＴリガンド |
| JP6689856B2 (ja) * | 2014-12-03 | 2020-04-28 | ヤンセン ファーマシューティカ エヌ．ベー． | ６，７−ジヒドロピラゾロ［１，５−ａ］ピラジン−４（５Ｈ）−オン化合物およびＭＧＬＵＲ２受容体の負のアロステリック調節因子としてのそれらの使用 |
| US10538491B2 (en) | 2015-03-16 | 2020-01-21 | Vanderbilt University | 4,5-substituted picolinamide and picolinonitrile metabotropic glutamate receptor 2 negative allosteric modulators |
| CN107922396B (zh) | 2015-07-20 | 2022-08-05 | 建新公司 | 集落刺激因子-1受体(csf-1r)抑制剂 |
| US10550116B2 (en) | 2015-10-26 | 2020-02-04 | Bayer Cropscience Aktiengesellschaft | Fused bicyclic heterocycle derivatives as pesticides |
| LT3389727T (lt) | 2015-12-18 | 2020-10-12 | Janssen Pharmaceutica Nv | Radioaktyviai pažymėti mglur2/3 pet ligandai |
| JP6929285B2 (ja) | 2015-12-18 | 2021-09-01 | ヤンセン ファーマシューティカ エヌ．ベー． | 放射性標識ｍＧｌｕＲ２／３ＰＥＴリガンド |
| CR20190147A (es) | 2016-09-27 | 2019-05-17 | Merck Sharp & Dohme | DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE mGluR2, COMPOSICIONES Y SU USO |
| EP3719023B1 (en) | 2017-11-24 | 2024-10-16 | Sumitomo Pharma Co., Ltd. | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINONE DERIVATIVE AND MEDICAL USE THEREOF |
| CN108689957B (zh) * | 2018-07-23 | 2020-07-03 | 南京药石科技股份有限公司 | 一种2r/2s-三氟甲基吗啉及其盐酸盐的制备方法和应用 |
| AU2019375983A1 (en) * | 2018-11-09 | 2021-06-10 | Vivace Therapeutics, Inc. | Bicyclic compounds |
| IL287222B2 (en) | 2019-04-16 | 2025-04-01 | Vivace Therapeutics Inc | Bicyclic compounds |
| WO2020243049A1 (en) * | 2019-05-30 | 2020-12-03 | Merck Sharp & Dohme Corp. | Factor xi activation inhibitors |
| CA3139622A1 (en) | 2019-07-01 | 2021-01-07 | UCB Biopharma SRL | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator |
| CN110256342B (zh) * | 2019-07-16 | 2022-06-07 | 河南省科学院化学研究所有限公司 | 一种2-氰基喹啉衍生物的合成方法 |
| EP4267573A1 (en) | 2020-12-23 | 2023-11-01 | Genzyme Corporation | Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors |
| WO2024112853A1 (en) * | 2022-11-24 | 2024-05-30 | Exelixis, Inc. | Compounds that inhibit pkmyt1 |
| WO2025101691A1 (en) * | 2023-11-08 | 2025-05-15 | Exelixis, Inc. | Methods for treating cancer using compounds that inhibit pkmyt1 |
| CN119613413B (zh) * | 2024-12-26 | 2026-02-06 | 上海皓元医药股份有限公司 | 一种非唑奈坦的制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0551831A1 (de) * | 1992-01-15 | 1993-07-21 | Hoechst Schering AgrEvo GmbH | Verfahren zur Herstellung substituierter 2-Cyanopyridine |
| US5552437A (en) | 1994-10-27 | 1996-09-03 | Merck Frosst Canada, Inc. | Bisarylcarbinol derivatives as inhibitors of leukotriene biosynthesis |
| US5576338A (en) | 1995-02-15 | 1996-11-19 | Merck Frosst Canada, Inc. | Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis |
| GB9524137D0 (en) | 1995-11-24 | 1996-01-24 | Smithkline Beecham Spa | Novel compounds |
| JPH115772A (ja) * | 1997-04-25 | 1999-01-12 | Takeda Chem Ind Ltd | アミド誘導体、その製造法および用途 |
| CA2285402A1 (en) * | 1997-04-25 | 1998-11-05 | Kohei Notoya | Amide derivatives, their production and use |
| MXPA02003740A (es) * | 1999-10-15 | 2002-09-30 | Hoffmann La Roche | Derivados de benzodiazepina. |
| TWI328009B (en) * | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
| CA2532036A1 (en) * | 2003-07-11 | 2005-02-03 | Merck & Co., Inc. | Methods for identifying cell surface receptor protein modulators |
| CA2539707C (en) | 2003-09-23 | 2011-08-09 | Merck & Co., Inc. | Quinoline potassium channel inhibitors |
| US20070287716A1 (en) * | 2004-10-28 | 2007-12-13 | Hu Essa H | Pyrimidine and Quinoline Potentiators of Metabotropic Glutamate Receptors |
| CA2624294A1 (en) * | 2005-10-05 | 2007-04-12 | Merck Frosst Canada Ltd. | Substituted quinolines as inhibitors of leukotriene biosynthesis |
| AR065093A1 (es) * | 2007-02-05 | 2009-05-13 | Merck Frosst Canada Ltd | Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos |
| ES2392905T3 (es) * | 2007-06-18 | 2012-12-14 | Richter Gedeon Nyrt. | Derivados de sulfonil-quinolina |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| WO2012083866A1 (en) | 2010-12-22 | 2012-06-28 | The Hong Kong Polytechnic University | Quinoline derivatives as anti-cancer agents |
| MX344308B (es) | 2011-11-03 | 2016-12-13 | Merck Sharp & Dohme | Derivados de quinolina carboxamida y quinolina carbonitrilo como moduladores alostericos negativos de mglur2, composiciones y su uso. |
-
2012
- 2012-10-26 MX MX2014005415A patent/MX344308B/es active IP Right Grant
- 2012-10-26 CA CA2853923A patent/CA2853923A1/en not_active Abandoned
- 2012-10-26 US US14/356,080 patent/US9278960B2/en active Active
- 2012-10-26 EP EP12846579.6A patent/EP2775841B1/en active Active
- 2012-10-26 AU AU2012332895A patent/AU2012332895B2/en not_active Ceased
- 2012-10-26 MY MYPI2014001269A patent/MY167423A/en unknown
- 2012-10-26 WO PCT/US2012/062027 patent/WO2013066736A1/en not_active Ceased
- 2012-10-26 RU RU2014122335A patent/RU2610262C2/ru not_active IP Right Cessation
- 2012-10-26 KR KR1020147014513A patent/KR20140088887A/ko not_active Withdrawn
- 2012-10-26 JP JP2014539998A patent/JP5857136B2/ja not_active Expired - Fee Related
- 2012-10-26 IN IN3234CHN2014 patent/IN2014CN03234A/en unknown
- 2012-10-26 CN CN201280065879.7A patent/CN104010504B/zh not_active Expired - Fee Related
- 2012-11-01 AR ARP120104094A patent/AR088611A1/es unknown
- 2012-11-02 TW TW101140837A patent/TWI605040B/zh not_active IP Right Cessation
-
2014
- 2014-04-28 IL IL232291A patent/IL232291A0/en unknown
- 2014-04-30 CO CO14093156A patent/CO6950474A2/es unknown
-
2015
- 2015-12-14 JP JP2015242916A patent/JP6114809B2/ja not_active Expired - Fee Related
-
2016
- 2016-02-17 AU AU2016200998A patent/AU2016200998B2/en not_active Ceased
- 2016-02-18 US US15/047,213 patent/US9663506B2/en active Active
- 2016-02-18 US US15/047,224 patent/US9636337B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013525444A5 (enExample) | ||
| JP2013014622A5 (enExample) | ||
| EP2683382A4 (en) | DOSAGE SCHEMES FOR THE TREATMENT OF MORBUS FABRY | |
| JP2014507446A5 (enExample) | ||
| JP2012255026A5 (enExample) | ||
| EP2828247A4 (en) | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCLE ATROPHY | |
| EP2819519A4 (en) | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCLE ATROPHY | |
| BRPI1012116A2 (pt) | composição farmacêutica para o tratamento de doenças cardíacas | |
| EP2552203A4 (en) | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF VIRUS INFECTIONS | |
| JP2016518337A5 (enExample) | ||
| JP2011518833A5 (enExample) | ||
| EP2911664A4 (en) | COMBINATION THERAPIES FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED DISEASES | |
| EP2812004A4 (en) | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCLE ATROPHY | |
| IL221744A (en) | Use of combination of compounds for preparation of a medicament for treating parkinson's disease | |
| TR201909277T4 (tr) | Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları. | |
| ZA201401678B (en) | Novel distributed 3,4-diamino-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | |
| EP2579867A4 (en) | Triheptanoin diet for adult polyglucosan body disease (apbd) treatment | |
| EP2678009A4 (en) | CYSTAMINE ANALOGUE FOR THE TREATMENT OF MORBUS PARKINSON | |
| CL2013002424A1 (es) | Compuestos derivados de (piridin-4-il)-bencilamidas como moduladores alostericos de nachr alfa-7; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades como alzheimer, ansiedad, esquizofrenia, parkinson, entre otras. | |
| EA201691831A1 (ru) | Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов | |
| JP2012516348A5 (enExample) | ||
| EA201691788A1 (ru) | Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов | |
| JP2015516419A5 (enExample) | ||
| EP2676665A4 (en) | USE OF ALPHA-MANGOSTINE IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF ALZHEIMER | |
| EP2900259A4 (en) | GLYCOSIDASE DOSAGE PLAN FOR THE TREATMENT OF INFECTION DISEASES |